194.08
-4.24(-2.14%)
Currency In USD
| Previous Close | 198.32 |
| Open | 195.66 |
| Day High | 197.34 |
| Day Low | 191.09 |
| 52-Week High | 199.99 |
| 52-Week Low | 111.09 |
| Volume | 577,729 |
| Average Volume | 466,143 |
| Market Cap | 11.75B |
| PE | -36.55 |
| EPS | -5.31 |
| Moving Average 50 Days | 176.13 |
| Moving Average 200 Days | 152.06 |
| Change | -4.24 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $10,800.22 as of August 18, 2025 at a share price of $194.08. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,305.53 as of August 18, 2025 at a share price of $194.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:01 PM GMT
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. fi
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
GlobeNewswire Inc.
Jul 28, 2025 11:00 AM GMT
First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease companyOn track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well as combination therapy trials in
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life
GlobeNewswire Inc.
Jul 14, 2025 8:01 PM GMT
COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to p